Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines


William T. Beck[1, 2] Tsui-Ting Ho[1, 3, 4], Xiaolong He[1, 2], Yin-Yuan Mo[3,4,5]

[1]Department of Biopharmaceutical Sciences, College of Pharmacy, and [2]Cancer Center, University of Illinois at Chicago, Chicago, 60612, IL, USA; [3]Cancer Institute, [4]Department of Radiation Oncology, and [5]Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, 39216, MS, USA

Abstract

The acquisition of resistance to anticancer drugs is widely viewed as a key obstacle to successful cancer therapy. However, detailed knowledge of the initial molecular events in the response of cancer cells to these chemotherapeutic and stress responses, and how these lead to the development of chemoresistance, remains incompletely understood. Using microRNA array and washout and rechallenge experiments, we found that short term treatment of leukemia cells with etoposide led a few days later to transient resistance that was associated with a corresponding transient increase in expression of ABCB1 mRNA, as well as miR-135b and miR-196b. This phenomenon was associated with short-term exposure to genotoxic agents, such as etoposide, topotecan, doxorubicin and ionizing radiation, but not agents that do not directly damage DNA. Further, this appeared to be histiotype-specific, and was seen in leukemic cells, but not in cell lines derived from solid tumors. Treatment of leukemic cells with either 5-aza-deoxycytidine or tricostatin A produced similar increased expression of ABCB1, miR-135b, and miR-196b, suggesting a role for epigenetic regulation of this phenomenon. Bioinformatics analyses revealed that CACNA1E, ARHGEF2, PTK2, SIAH1, ARHGAP6, and NME4 may be involved in the initial events in the development of drug resistance following the upregulation of ABCB1, miR-135b and miR-196b. In summary, we report herein that short-term exposure of cells to DNA damaging agents leads to transient drug resistance, which is associated with elevations in ABCB1, miR-135b and miR-196b, and suggests novel components that may be involved in the development of anticancer drug resistance.

Image



Recent Publications

1. He X, … Beck WT. Alternative splicing of the multidrug resistance protein 1 (MRP1/ABCC1) gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res, 10:4652-4660, 2004.
2. He X, … Beck WT. Knockdown of Polypyrimidine-Tract Binding Protein (PTB) Suppresses Ovarian Tumor Cell Growth and Invasiveness *In Vitro*. Oncogene 26:4961-4968, 2007.
3. He X, … Beck WT. Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene, 30:356-365, 2011
4. Arslan AD, … Beck WT. A high-throughput assay to identify small-molecule modulators of alternative pre-mRNA splicing. J Biomolec Screening, 18:180-190, 2013.
5. He X, … Beck WT. Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogenesis. 2014 Jan 13;3:e84.
6. Gardeux V, … Beck WT, and Lussier YA. Concordance of deregulated mechanisms unveiled in underpowered experiments: PTBP1 knockdown case study. BMC Med Genomics. 2014;7 Suppl 1:S1
7. Ho T-T, HeX, Mo Y-Y, Beck WT. Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. Int J Biochem Mol Biol 2016;7(2): 27-47.



Biography

William T. Beck, PhD, is University Distinguished Professor and former Head of the Department of Biopharmaceutical Sciences in the College of Pharmacy at the University of Illinois at Chicago. His research efforts have focused on understanding the molecular and genetic mechanisms of anticancer drug action and tumor cell resistance to anticancer drugs. His current research focuses on understanding mechanisms of anticancer drug resistance, and splicing factor genes and their involvement in cancer initiation, progression, and resistance to therapy, in addition to their potential as novel therapeutic targets in ovarian, breast, and brain cancers.

Email: wtbeck@uic.edu